AI assistant
SHIELD THERAPEUTICS PLC Share Issue/Capital Change 2022
7914_sha_2022-03-31_3ee0d711-a919-43b4-ad60-940657006b25.html
Share Issue/Capital Change
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 8289G
Shield Therapeutics PLC
31 March 2022
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Block Listing Application
London, UK, 31 March 2022: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), has today made an application to the London Stock Exchange for a block listing of 2,000,000 ordinary shares of 1.5 pence each in the Company ("Block Listing Shares") to be admitted to trading on the London Stock Exchange ("Admission").
The 2,000,000 Block Listing Shares are to be issued under the Shield Therapeutics Retention and Performance Share Plan.
Admission is expected to occur on 06 April 2022.
For further information please contact:
| Shield Therapeutics plc | www.shieldtherapeutics.com |
| Greg Madison, CEO | +44 (0) 191 511 8500 |
| Hans-Peter Rudolf, CFO | |
| Nominated Adviser and Joint Broker | |
| Peel Hunt LLP | |
| James Steel/Christopher Golden | +44 (0)20 7418 8900 |
| Joint Broker finnCap Ltd Geoff Nash/Alice Lane/George Dollemore |
+44 (0)20 7220 0500 |
| Financial PR & IR Advisor | |
| Walbrook PR (UK Advisor) | |
| Paul McManus/Lianne Applegarth/Alice Woodings Investor Contact (US Advisor) |
+44 (0)20 7933 8780 or [email protected] |
| LifeSci Advisors, LLC John Mullaly |
+1 617 429 3548 or [email protected] |
About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.
Shield's lead product, Accrufer®/Feraccru®, has been approved for use in the United States, European Union, UK, Switzerland, and Australia and has exclusive IP rights until the mid-2030s. The Group has recently launched Accrufer® in the US. Feraccru® is being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Accrufer®/Feraccru® in China, Hong Kong, Macau, and Taiwan, Korea Pharma Co., Ltd. in the Republic of Korea and with KYE Pharmaceuticals Inc in Canada.
For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ALSZFLFXLXLZBBF